文献速递糖尿病

老年人降压药物治疗:随机临床试验的系统综述与荟萃分析

Antihypertensive Agents in Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

该系统综述纳入19项随机试验共42,134例65岁及以上患者,评估降压药物或血压目标的获益。结果显示降压治疗与全因死亡率(RR 0.88,95%CI 0.81-0.94)、心血管死亡率、心肌梗死、心力衰竭、卒中及慢性肾脏病风险降低相关;75岁及以上人群同样显著获益。严格收缩压目标(<120 mmHg和<130 mmHg)与更宽松目标(<150 mmHg和<160 mmHg)均有获益,但获益终点不同。2型糖尿病患者慢性肾脏病风险降低,其他结局无显著差异,且糖尿病与无糖尿病者间无显著交互作用。

要点

  • 65岁及以上老年人降压治疗可显著降低全因死亡、心血管死亡、心衰和卒中风险。
  • 75岁及以上人群同样从降压治疗中显著获益。
  • 严格收缩压目标(<120或<130 mmHg)与更宽松目标(<150或<160 mmHg)均降低心衰和卒中风险,但全因和心血管死亡获益主要见于严格目标。

核心结论

  • 65岁及以上或75岁及以上个体接受降压治疗可统计学显著降低全因死亡、心血管死亡、心力衰竭和卒中风险。
  • 糖尿病与无糖尿病者之间的估计值无统计学显著差异(即无显著交互作用)。

研究设计与样本

  • 系统综述与荟萃分析,纳入评估65岁及以上个体降压药物或血压目标的随机试验。
  • 共纳入19项试验,42,134例患者;由独立评审员配对筛选和评价。

主要发现

  • 65岁及以上人群:降压治疗与全因死亡率降低相关(相对风险0.88,95%CI 0.81-0.94;高确定性证据;平均随访31个月),并降低心血管死亡率、心肌梗死、心力衰竭、卒中及慢性肾脏病风险。
  • 75岁及以上人群:全因死亡、心血管死亡、卒中和心力衰竭风险显著降低。
  • 严格收缩压目标(<120 mmHg和<130 mmHg)与全因死亡、心血管死亡和心力衰竭风险显著降低相关。
  • 更宽松收缩压目标(<150 mmHg和<160 mmHg)与心力衰竭和卒中风险降低相关。
  • 2型糖尿病患者:慢性肾脏病风险降低,其他结局无显著降低;糖尿病与无糖尿病者间无显著交互作用。

关键数值与推荐

  • 全因死亡率相对风险0.88(95%CI 0.81-0.94),高确定性证据,平均随访31个月,对象为65岁及以上接受降压治疗者。
  • 严格收缩压目标定义为<120 mmHg和<130 mmHg。
  • 更宽松收缩压目标定义为<150 mmHg和<160 mmHg。

临床怎么用

  • 对65岁及以上老年人,降压治疗应作为降低全因死亡、心血管死亡、心衰和卒中风险的有效策略。
  • 对75岁及以上高龄老年人,同样应考虑降压治疗以降低全因死亡、心血管死亡、卒中和心衰风险。
  • 设定收缩压目标时,严格目标(<120或<130 mmHg)与更宽松目标(<150或<160 mmHg)均可考虑,但需根据个体获益终点权衡。
  • 合并2型糖尿病的老年患者降压治疗可降低慢性肾脏病风险,但其他结局获益与无糖尿病者无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This systematic review summarizes the benefits of treating blood pressure (BP) in individuals 65 years and older. METHODS: We included randomized trials that evaluated BP-lowering medications or BP targets in individuals 65 years and older. Trials were selected and appraised by pairs of independent reviewers. RESULTS: We included 19 trials (42,134 patients). In individuals 65 years or older, antihypertensive therapy was associated with a reduction in all-cause mortality [relative risk: 0.88 (95% CI: 0.81 to 0.94); high certainty evidence; mean follow-up 31 months], cardiovascular mortality, myocardial infarction, heart failure, stroke, and chronic kidney disease. Individuals 75 years or older had a significant reduction in the risk of all-cause and cardiovascular mortality, stroke, and heart failure. Strict systolic BP targets (<120 mm Hg and <130 mm Hg) were associated with a significant reduction in the risk of all-cause and cardiovascular mortality and heart failure, whereas more liberal systolic targets (<150 mm Hg and <160 mm Hg) were associated with lower risk of heart failure and stroke. Older adults with type 2 diabetes mellitus (DM) had lower risk of chronic kidney disease without a significant reduction in other outcomes. However, there was no significant difference in estimates (i.e., interaction) between those with and without DM. CONCLUSIONS: Individuals aged 65 years and older or 75 years and older who receive antihypertensive therapy have statistically significant reduction in the risk of all-cause and cardiovascular mortality, heart failure, and stroke. There was no statistically significant difference in estimates between those with and without DM.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Murad MH, Larrea-Mantilla L, Haddad A, et al. Antihypertensive Agents in Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Clin Endocrinol Metab. 2019. PMID: 30903690. doi:10.1210/jc.2019-00197

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。